GLP

A new study reports that GLP-1 drugs, the class of medications best known for diabetes and weight loss, are associated with fewer hospital visits among people with schizophrenia. The finding, covered by Bloomberg, adds to growing interest in whether these drugs have benefits beyond metabolism. Readers are weighing how strong the evidence is and what it could mean for psychiatric care.

Eli Lilly is exploring opportunities in aesthetic medicine, as growing numbers of patients taking its GLP-1 weight-loss drugs deal with side effects such as sagging or loose skin after rapid weight loss. The move would position the Indianapolis-based drugmaker to serve patients seeking procedures to address changes in appearance tied to medications like Zepbound and Mounjaro.

Researchers at the University of Pennsylvania have used artificial intelligence and data from online forums to identify potential side effects of retatrutide, an unapproved GLP-1 weight-loss drug still in development. The study highlights a new way to detect adverse reactions before regulators or manufacturers can, drawing attention as interest in next-generation obesity medications keeps growing.

The Federal Reserve's latest Beige Book reports that GLP-1 weight-loss drugs such as Ozempic are changing consumer demand, with businesses noting reduced consumption of poultry and alcohol as users eat and drink less. The observation signals that the medications are now having measurable effects on the broader economy, not just the healthcare sector.

Attention is turning to what follows today's GLP-1 weight-loss injections. A pipeline of new obesity medicines is emerging, including oral versions of GLP-1 drugs, multi-receptor therapies, and combination treatments designed to preserve muscle while patients lose weight. The discussion reflects growing interest in how obesity medicine will evolve once current blockbuster drugs face competition from newer, potentially more convenient options.

A mouse study found that olive oil given before glucose blunted the early blood sugar spike and slowed stomach emptying, with the hormones glucagon and GLP-1 acting as partly redundant backup mechanisms. The effect held in diabetic mice. Researchers caution the finding is preliminary and has not yet been shown to apply to humans.

Novo Nordisk and Eli Lilly presented data at the Aging Research and Drug Discovery (ARDD) meeting suggesting their GLP-1 drugs may slow biological aging, beyond their established effects on diabetes and obesity. The findings fuel debate over whether blockbuster drugs like Ozempic and Mounjaro could double as anti-aging therapies, with researchers cautioning that biological aging markers are not yet proven predictors of longevity.

Suppliers in the nutrition industry say companion products designed for people taking GLP-1 weight-loss and diabetes drugs should complement the medication rather than compete with it. The message is directed at product developers as interest grows in foods and supplements tailored to users of drugs like Ozempic and Wegovy, who often face reduced appetite and nutritional gaps.

Health experts are highlighting the importance of proper nutrition for people starting GLP-1 weight-loss medications such as Ozempic and Mounjaro. Because these drugs significantly reduce appetite, patients risk falling short on protein, vitamins and other essential nutrients. Dietitians advise focusing on nutrient-dense foods, adequate protein intake and hydration to preserve muscle mass while losing weight. The guidance comes as prescriptions for the medications continue to rise worldwide.

New reporting examines how GLP-1 medications, widely used for weight loss and diabetes, may influence mental health, particularly depression and anxiety. The discussion focuses on whether these drugs have positive or negative psychological effects for patients taking them. Health outlets are weighing the evidence as use of GLP-1 drugs continues to expand globally.

Interest is growing in retatrutide, Eli Lilly's experimental obesity and diabetes drug, which follows in the footsteps of tirzepatide and semaglutide. Discussion centres on its triple-hormone mechanism and trial results suggesting greater weight loss than existing GLP-1 medicines. Commentators frame it as the next step in the fast-expanding market for weight-loss injections, though it remains under development and not yet approved.

A review of CPHI Milan 2026 highlights how pharmaceutical manufacturing standards and the surge around GLP-1 drugs are reshaping the nutraceuticals industry. Exhibitors and analysts reportedly discussed tighter quality expectations and shifting consumer interest as companies in the supplements sector adapt their strategies in response to the weight-loss drug boom.

European Union regulators have issued a positive recommendation for approving Eli Lilly's oral weight loss medication, a pill developed as an alternative to injectable GLP-1 treatments. The recommendation moves the drug closer to European market authorization, expanding access to obesity treatment in tablet form. Financial and health news outlets are covering the decision given the booming demand for weight loss drugs and Eli Lilly's leading position in the market.

News coverage is examining how nutrition and dietary guidance are changing as GLP-1 weight-loss and diabetes drugs such as Ozempic and Wegovy become widely used. The discussion centres on how these medications affect appetite, eating habits, and the advice dietitians and doctors give patients, and what balanced nutrition should look like for people on the drugs.

With GLP-1 weight-loss drugs reshaping eating habits, the food industry is rethinking portion sizes, nutrient density and sensory satisfaction. As appetite suppression reduces how much people eat, manufacturers and nutrition experts are examining how smaller portions can still deliver adequate protein, vitamins and enjoyable eating experiences. The debate spans product reformulation, packaging and how meals should be designed for people on medications like Ozempic and Wegovy.

Ingredient specialist SANSE is highlighting the forces redefining the active nutrition market, including sharply rising protein costs and the disruption caused by GLP-1 weight-loss drugs. The company's analysis suggests supplement and sports nutrition makers face pressure to reformulate, rethink protein sourcing and adapt products for consumers using appetite-suppressing medications, as demand patterns shift across the industry.

Designers are presenting spring-summer 2027 collections dominated by sheer fabrics, lingerie-inspired pieces, lace, and skin-revealing cutouts, making the body the season's central theme. Commenters are debating whether the trend reflects or pushes back against the cultural mood shaped by the rise of GLP-1 weight loss medications, and what it signals about shifting attitudes toward body image in fashion.

U.S. News & World Report has released a new survey examining what makes GLP-1 telehealth programs work, finding that patient priorities and ongoing support are central drivers of success. The findings point to sustained coaching and follow-up care, rather than medication access alone, as decisive factors for people using telehealth services for weight-loss drugs.

Gateway Health Alliances will discuss GLP-1 product innovation at SupplySide Global, a major trade show for the nutrition and nutraceutical industry. The announcement signals the company's push into the fast-growing GLP-1 category, as supplement makers look to develop products that support consumers using weight-loss drugs like Ozempic and similar therapies.

A new trend dubbed 'GLP-1 travel' is changing how the hospitality and wellness industries cater to guests using weight-loss drugs like Ozempic and Wegovy. Hotels are rethinking portion sizes, menus and fitness offerings, while resorts and spas are adapting wellness programmes to suit travellers on GLP-1 medications. Forbes reports the shift is already visible across hotel dining, room service and travel planning.

New findings suggest GLP-1 medications, widely used for diabetes and weight loss, may also help protect kidney health in people living with bipolar disorder. The news adds to a growing list of potential benefits being studied for the drug class. Researchers and clinicians are watching closely as interest in GLP-1s expands far beyond their original uses.

Commentary is circulating on whether GLP-1 weight-loss medications could change food consumption patterns across the Middle East. If adoption grows, demand could shift away from high-calorie products, affecting food companies, retailers and restaurant chains in the region. Observers are weighing how quickly such drugs will spread and how significantly they might alter regional eating habits and the broader food economy.

A report finds that 29% of people who have used GLP-1 weight-loss drugs long term say they lack confidence in meeting their nutritional needs. The finding points to concerns that appetite suppression on medications like Ozempic and Wegovy may leave users eating too little or missing key nutrients. It adds to ongoing debate about how patients on these drugs should be supported with dietary guidance.

Vogue reports that the fashion industry is beginning to reckon with the effects of GLP-1 weight-loss medications on clothing trends. For spring/summer 2027, the biggest looks include sheer fabrics, lingerie, skin-revealing cutouts and lace, suggesting designers are responding to shifting body shapes as drugs like Ozempic become widespread.

Obesity medications are a leading health news topic today, with coverage focusing on the growing use of weight-loss drugs such as GLP-1 treatments. Reports highlight rising demand, questions about long-term safety and access, and debate over whether these drugs should reshape how obesity is treated worldwide.

Eli Lilly's experimental oral GLP-1 pill orforglipron reportedly delivered cardiovascular safety data (MACE outcomes) strong enough to reset expectations for the entire oral GLP-1 field. Commentators argue rival developers of oral weight-loss and diabetes drugs will now struggle to match this evidentiary standard in their own outcome trials.

Major food companies are adjusting their products in response to the rapid rise of weight loss drugs such as GLP-1 medications, which suppress appetite and reduce how much users eat. Manufacturers are reportedly reformulating or repositioning items to suit changing consumption patterns, and the shift is drawing attention as a potential turning point for the packaged food industry.

New findings suggest patients taking GLP-1 drugs, such as Ozempic and Wegovy, experience fewer heart complications and infections after surgery. The report, covered by Inside Precision Medicine, adds to growing evidence that the popular weight-loss and diabetes medications may offer broader health benefits beyond their intended uses. Clinicians are weighing what this could mean for perioperative care.

Perfume houses are developing food-inspired fragrances, such as cherry or tabasco notes, aimed at people using weight-loss drugs like Ozempic whose reduced appetite has dulled their enjoyment of eating. The idea is that users can still experience the pleasure of familiar flavours through scent. It highlights how the booming GLP-1 drug market is reshaping adjacent industries, from food to beauty.

Retatrutide, an experimental weight-loss injection developed by Eli Lilly, is drawing widespread searches and media explainers in the US, UK and Australia. Outlets are walking readers through what the drug is, how it differs from existing GLP-1 treatments like Ozempic and tirzepatide, and what trial results suggest about its potential for obesity treatment.

Danish biotech Zealand Pharma has struck a deal with AI drug discovery company Generate (Generate Biomedicines) to develop obesity treatments, in an agreement worth up to $1.2 billion. The tie-up pairs Zealand's peptide expertise with Generate's generative AI platform, as big pharma and biotech race to find the next generation of weight-loss drugs beyond GLP-1 blockbusters like Wegovy and Zepbound.

Ingredients firms ADM, Cargill and Synergy Flavours say the rapid rise of GLP-1 weight-loss drugs is changing how nutrition products are formulated. Companies are adapting to users' reduced appetites and altered tastes, developing smaller portions and products richer in protein and micronutrients to help people on the medications meet their nutritional needs.

Priceline has released its travel trend forecast for 2027, highlighting three emerging behaviors: 'tripmaxxing', or maximizing every aspect of a trip; GLP-1-friendly hotels catering to guests on weight-loss medications; and food-focused travel built around culinary experiences. The report suggests travelers will increasingly plan trips around health needs, value extraction, and eating well.

The American Council on Exercise and Eden Health are rolling out training programs to prepare fitness professionals for clients using GLP-1 weight-loss medications. The initiative aims to equip trainers to support people on drugs like Ozempic and Wegovy, whose changing bodies and nutrition needs require adapted exercise guidance, reflecting how widely these medications are reshaping the fitness industry.